Effects of the PPARα agonist and widely used antihyperlipidemic drug gemfibrozil on hepatic toxicity and lipid metabolism

PPAR Research

Volumn , Issue , 2010, Pages

  Cunningham, Michael L ^a   Collins, Bradley J ^a   Hejtmancik, Milton R ^a   Herbert, Ronald A ^a   Travlos, Gregory S ^a   Vallant, Molly K ^a   Stout, Matthew D ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; BILE SALT; CHOLESTEROL; GEMFIBROZIL; IDITOL DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HEPATOMEGALY; HISTOPATHOLOGY; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER CELL; LIVER TOXICITY; LIVER WEIGHT; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; SYRIAN HAMSTER;

EID: 78349300871     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2010/681963     Document Type: Article

References (79)

1. Frick M. H., Elo O., Haapa K., Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease The New England Journal of Medicine 1987 317 20 1237 1245
2. Rubins H. B., Robins S. J., Collins D., Fye C. L., Anderson J. W., Elam M. B., Faas F. H., Linares E., Schaefer E. J., Schectman G., Wilt T. J., Wittes J., Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol The New England Journal of Medicine 1999 341 6 410 418
3. Mahley R. W., Bernot T. P., Hardman J. G., Limbird L. E., Gilman A. G., Drug therapy for hypercholesterolemis and dyslipidemia Goodman and Gilman's the Pharmacological Basis of Therapeutics 2001 10th New York, NY, USA McGraw Hill 971 1002
4. Warren J. R., Lalwani N. D., Reddy J. K., Phthalate esters as peroxisome proliferator carcinogens Environmental Health Perspectives 1982 45 35 40
5. Reddy J. K., Lalwai N. D., Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans Critical Reviews in Toxicology 1983 12 1 1 58
6. Cerutti P. A., Prooxidant states and tumor promotion Science 1985 227 4685 375 381
7. Lake B. G., Mechanisms of hepatocarcinogenicity of peroxisome- proliferating drugs and chemicals Annual Review of Pharmacology and Toxicology 1995 35 483 507
8. Kawashima Y., Katoh H., Kozuka H., Differential effects of altered hormonal state on the induction of acyl-CoA hydrolases and peroxisomal -oxidation by clofibric acid Biochimica et Biophysica Acta 1983 750 2 365 372
9. Reddy J. K., Sambasiva Rao M., Azarnoff D. L., Sell S., Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643), in rat and mouse liver Cancer Research 1979 39 1 152 161
10. National Toxicology Program (NTP), Carcinogenesis Bioassay of Di(2-ethylhexyl)phthalate (CAS No. 117-81-7) in F344 Rats and B6C3F1 Mice (Feed Study Technical Report Series no. 217. NIH Publication no. 82-1773 1982 Research Triangle Park, NC, USA, and Bethesda, MD, USA U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health
11. Cattley R. C., Marsman D. S., Popp J. A., Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator WY-14,643 in rat liver Carcinogenesis 1991 12 3 469 473
12. Fitzgerald J. E., Sanyer J. L., Schardein J. L., Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil Journal of the National Cancer Institute 1981 67 5 1105 1116
13. Reddy J. K., Qureshi S. A., Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl- -P -chlorophenoxyisobutyrate (clofibrate) in rats British Journal of Cancer 1979 40 3 476 482
14. Svoboda D. J., Azarnoff D. L., Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug Cancer Research 1979 39 9 3419 3428
15. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 6294 645 650
16. Beyer T. P., Chen Y., Porter R. K., Lu D., Schmidt R. J., Mantlo N. B., Konrad R. J., Cao G., Peroxisome proliferator-activated receptor agonists regulate cholesterol ester transfer protein Lipids 2008 43 7 611 618
17. Kersten S., Desvergne B., Wahli W., Roles of PPARS in health and disease Nature 2000 405 6785 421 424
18. Holden P. R., Tugwood J. D., Peroxisome proliferator-activated receptor alpha: Role in rodent liver cancer and species differences Journal of Molecular Endocrinology 1999 22 1 1 8
19. Lake B. G., Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation Xenobiotica 2009 39 8 582 596
20. Chen H., Huang C., Wilson M. W., Lay L. T., Robertson L. W., Chow C. K., Glauert H. P., Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in SpragueDawley rats Carcinogenesis 1994 15 12 2847 2850
21. Roberts R. A., Peroxisome proliferators: mechanisms of adverse effects in rodents and molecular basis for species differences Archives of Toxicology 1999 73 8-9 413 418
22. Lake B. G., Rumsby P. C., Price R. J., Cunninghame M. E., Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor- 1 gene expression in the rat, Syrian hamster and guinea pig Mutation Research 2000 448 2 213 225
23. Sallustio B. C., Harkin L. A., Mann M. C., Krivickas S. J., Burcham P. C., Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones? Toxicology and Applied Pharmacology 1997 147 2 459 464
24. Peters J. M., Cheung C., Gonzalez F. J., Peroxisome proliferator- activated receptor- and liver cancer: where do we stand? Journal of Molecular Medicine 2005 83 10 774 785
25. Cheung C., Akiyama T. E., Ward J. M., Nicol C. J., Feigenbaum L., Vinson C., Gonzalez F. J., Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor Cancer Research 2004 64 11 3849 3854
26. Shah Y. M., Morimura K., Yang Q., Tanabe T., Takagi M., Gonzalez F. J., Peroxisome proliferator-activated receptor regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation Molecular and Cellular Biology 2007 27 12 4238 4247
27. Nemali M. R., Reddy M. K., Usuda N., Reddy P. G., Comeau L. D., Rao M. S., Reddy J. K., Differential induction and regulation of peroxisomal enzyme: predictive value of peroxisome proliferation in identifying certain nonmutagenic carcinogens Toxicology and Applied Pharmacology 1989 97 1 72 87
28. Badr M. Z., Induction of peroxisomal enzyme activities by di-(2-ethylhexyl) phthalate in thyroidectomized rats with parathyroid replants Journal of Pharmacology and Experimental Therapeutics 1992 263 3 1105 1110
29. Thottassery J., Winberg L., Youssef J., Cunningham M., Badr M., Regulation of perfluorooctanoic acid-induced peroxisomal enzyme activities and hepatocellular growth by adrenal hormones Hepatology 1992 15 2 316 322
30. Marsman D. S., Cattley R. C., Conway J. G., Popp J. A., Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats Cancer Research 1988 48 23 6739 6744
31. Peters J. M., Cattley R. C., Gonzalez F. J., Role of PPAR in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643 Carcinogenesis 1997 18 11 2029 2033
32. Morimura K., Cheung C., Ward J. M., Reddy J. K., Gonzalez F. J., Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor to Wy-14,643-induced liver tumorigenesis Carcinogenesis 2006 27 5 1074 1080
33. Ito Y., Yamanoshita O., Asaeda N., Tagawa Y., Lee C.-H., Aoyama T., Ichihara G., Furuhashi K., Kamijima M., Gonzalez F. J., Nakajima T., Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor -independent pathway Journal of Occupational Health 2007 49 3 172 182
34. Gonzalez F. J., Shah Y. M., PPAR : mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators Toxicology 2008 246 1 2 8
35. Yang Q., Nagano T., Shah Y., Cheung C., Ito S., Gonzalez F. J., The PPAR -humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR Toxicological Sciences 2008 101 1 132 139
36. National Toxicology Program (NTP), NTP Technical Report on the Toxicity Studies of Wy-14,643 (CAS No. 50892-23-4) Administered in Feed to Sprague-Dawley Rats, B6C3F1 Mice, and Syrian Hamsters Toxicity Report Series no. 62. NIH Publication no. 08-4419 2007 Research Triangle Park, NC, USA U.S. Department of Health and Human Services, Public Health Service, National institutes of Health
37. Schmezer P., Pool B. L., Klein R. G., Komitowski D., Schmhl D., Various short-term assays and two long-term studies with the plasticizer di(2-ethylhexyl)phthalate in the Syrian golden hamster Carcinogenesis 1988 9 1 37 43
38. O'Brien M. L., Cunningham M. L., Spear B. T., Glauert H. P., Effects of peroxisome proliferators on glutathione and glutathione-related enzymes in rats and hamsters Toxicology and Applied Pharmacology 2001 171 1 27 37
39. Tharappel J. C., Cunningham M. L., Spear B. T., Glauert H. P., Differential activation of hepatic NF- B in rats and hamsters by the peroxisome proliferators Wy-14,643, gemfibrozil, and dibutyl phthalate Toxicological Sciences 2001 62 1 20 27
40. O'Brien M. L., Cunningham M. L., Spear B. T., Glauert H. P., Peroxisome proliferators do not activate the transcription factors AP-1, early growth response-1, or heat shock factors 1 and 2 in rats or hamsters Toxicological Sciences 2002 69 1 139 148
41. O'Brien M. L., Twaroski T. P., Cunningham M. L., Glauert H. P., Spear B. T., Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters Toxicological Sciences 2001 60 2 271 278
42. Holmes E. W., Bingham C. M., Cunningham M. L., Hepatic Expression of Polymerase, Ref-1, PCNA, and Bax in WY 14,643-exposed rats and hamsters Experimental and Molecular Pathology 2002 73 3 209 219
43. Ge R., Tao L., Kramer P. M., Cunningham M. L., Pereira M. A., Effect of peroxisome proliferators on the methylation and protein level of the c-myc protooncogene in B6C3D1 mice liver Journal of Biochemical and Molecular Toxicology 2002 16 1 41 47
44. Rusyn I., Denissenko M. F., Wong V. A., Butterworth B. E., Cunningham M. L., Upton P. B., Thurman R. G., Swenberg J. A., Expression of base excision repair enzymes in rat and mouse liver is induced by peroxisome proliferators and is dependent upon carcinogenic potency Carcinogenesis 2000 21 12 2141 2145
45. Maronpot R. R., Boorman G. A., Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment Toxicologic Pathology 1982 10 2 71 80
46. Boorman G. A., Montgomery C. A. Jr., Eustis S. L., Wolfe M. J., McConnell E. E., Hardisty J. F., Milman H. A., Weisburger E. K., Quality assurance in pathology for rodent carcinogenicity studies Handbook of Carcinogen Testing 1985 Park Ridge, NJ, USA Noyes Publications 345 357
47. Small G. M., Burdett K., Connock M. J., A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase Biochemical Journal 1985 227 1 205 210
48. Lazarow P. B., Assay of peroxisomal beta-oxidation of fatty acids Methods in Enzymology 1981 72 315 319
49. Gray T. J. B., Beamand J. A., Lake B. G., Peroxisome proliferation in cultured rat hepatocytes produced by clofibrate and phthalate ester metabolites Toxicology Letters 1982 10 2-3 273 279
50. Gray T. J. B., Rowland I. R., Foster P. M. D., Gangolli S. D., Species differences in the testicular toxicity of phthalate esters Toxicology Letters 1982 11 1-2 141 147
51. Van Lente F., Pepoy M., Coupled-enzyme determination of catalase activity in erythrocytes Clinical Chemistry 1990 36 7 1339 1343
52. Yasmineh W. G., Chung M.-Y., Caspers J. I., Determination of serum catalase activity on a centrifugal analyzer by an NADP/NADPH coupled enzyme reaction system Clinical Biochemistry 1992 25 1 21 27
53. Smith P. K., Krohn R. I., Hermanson G. T., Measurement of protein using bicinchoninic acid Analytical Biochemistry 1985 150 1 76 85
54. Gart J. J., Chu K. C., Tarone R. E., Statistical issues in interpretation of chronic bioassay tests for carcinogenicity Journal of the National Cancer Institute 1979 62 4 957 974
55. Dunnett C. W., A multiple comparison procedure for comparing several treatments with a control Journal of the American Statistical Association 1955 50 1096 1121
56. Williams D. A., A test for differences between treatment means when several dose levels are compared with a zero dose control Biometrics 1971 27 1 103 117
57. Williams D. A., The comparison of several dose levels with a zero dose control Biometrics 1972 28 2 519 531
58. Shirley E., Non parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment Biometrics 1977 33 2 386 389
59. Williams D. A., A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control Biometrics 1986 42 1 183 186
60. Dunn O. J., Multiple comparisons using rank sums Technometrics 1964 6 241 252
61. Jonckheere A. R., A distribution-free k-sample test against ordered alternatives Biometrika 1954 41 133 145
62. Dixon W. J., Massey F. J. Jr., Introduction to Statistical Analysis 1957 2nd New York, NY, USA McGraw-Hill
63. Zhang Z., Wang H., Jiao R., Peng C., Wong Y. M., Yeung V. S. Y., Huang Y., Chen Z.-Y., Choosing hamsters but not rats as a model for studying plasma cholesterol-lowering activity of functional foods Molecular Nutrition Food Research 2009 53 7 921 930
64. Wagner J. D., Greaves K. A., Schwenke D. C., Bauer J. E., Loeb W. F., Quimby F. W., Lipids and lipoproteins The Clinical Chemistry of Laboratory Animals 1999 2nd Philadelphia, Pa, USA Taylor and Francis 181 228
65. Kurata Y., Kidachi F., Yokoyama M., Toyota N., Tsuchitani M., Katoh M., Subchronic toxicity of di(2-ethylhexyl)phthalate in common marmosets: lack of hepatic peroxisome proliferation, testicular atrophy, or pancreatic acinar cell hyperplasia Toxicological Sciences 1998 42 1 49 56
66. Pugh G. Jr., Isenberg J. S., Kamendulis L. M., Ackley D. C., Clare L. J., Brown R., Lington A. W., Smith J. H., Klaunig J. E., Effects of di-isononyl phthalate, di-2-ethylhexyl phthalate, and clofibrate in cynomolgus monkeys Toxicological Sciences 2000 56 1 181 188
67. Short R. D., Robinson E. C., Lington A. W., Chin A. E., Metabolic and peroxisome proliferation studies with di(2-ethylhexyl)phthalate in rats and monkeys Toxicology and Industrial Health 1987 3 2 185 195
68. Hanefeld M., Kemmer C., Kadner E., Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man Atherosclerosis 1983 46 2 239 246
69. Rusyn I., Peters J., Cunningham M., Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver Critical Reviews in Toxicology 2006 36 5 459 479
70. Mukherjee R., Jow L., Noonan D., McDonnell D. P., Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators Journal of Steroid Biochemistry and Molecular Biology 1994 51 3-4 157 166
71. Lambe K. G., Tugwood J. D., A human peroxisome-proliferator-activated receptor- is activated by inducers of adipogenesis, including thiazalidinedione drugs European Journal of Biochemistry 1996 239 1 1 7
72. Hennuyer N., Poulain P., Madsen L., Berge R. K., Houdebine L.-M., Branellec D., Fruchart J.-C., Fivet C., Duverger N., Staels B., Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response Circulation 1999 99 18 2445 2451
73. Schoonjans K., Staels B., Auwerx J., The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation Biochimica et Biophysica Acta 1996 1302 2 93 109
74. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.-C., Staels B., Auwerx J., Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor Journal of Clinical Investigation 1995 96 2 741 750
75. Auwerx J., Schoonjans K., Fruchart J. C., Staels B., Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects Journal of atherosclerosis and thrombosis 1996 3 2 81 89
76. Staels B., Schoonjans K., Fruchart J. C., Auwerx J., The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs) Biochimie 1997 79 2-3 95 99
77. Martin G., Schoonjans K., Lefebvre A.-M., Staels B., Auwerx J., Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR and PPAR activators Journal of Biological Chemistry 1997 272 45 28210 28217
78. Vamecq J., Latruffe N., Medical significance of peroxisome proliferator-activated receptors The Lancet 1999 354 9173 141 148
79. Fruchart J.-C., Duriez P., Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism Drugs of Today 2006 42 1 39 64